Cargando…

SB 206553, a putative 5-HT(2C) inverse agonist, attenuates methamphetamine-seeking in rats

BACKGROUND: Methamphetamine (meth) dependence presents a substantial socioeconomic burden. Despite the need, there is no FDA-approved pharmacotherapy for psychostimulant dependence. We consider 5-HT(2C) receptors as viable therapeutic targets. We recently revealed that the atypical antidepressant, m...

Descripción completa

Detalles Bibliográficos
Autores principales: Graves, Steven M, Napier, T Celeste
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441362/
https://www.ncbi.nlm.nih.gov/pubmed/22697313
http://dx.doi.org/10.1186/1471-2202-13-65
_version_ 1782243271589756928
author Graves, Steven M
Napier, T Celeste
author_facet Graves, Steven M
Napier, T Celeste
author_sort Graves, Steven M
collection PubMed
description BACKGROUND: Methamphetamine (meth) dependence presents a substantial socioeconomic burden. Despite the need, there is no FDA-approved pharmacotherapy for psychostimulant dependence. We consider 5-HT(2C) receptors as viable therapeutic targets. We recently revealed that the atypical antidepressant, mirtazapine, attenuates meth-seeking in a rodent model of human substance abuse. Mirtazapine historically has been considered to be an antagonist at 5-HT(2C) receptors, but more recently shown to exhibit inverse agonism at constitutively active 5-HT(2C) receptors. To help distinguish the roles for antagonism vs. inverse agonism, here we explored the ability of a more selective 5-HT(2C) inverse agonist, SB 206553 to attenuate meth-seeking behavior, and compared its effects to those obtained with 5-HT(2C) antagonists, SDZ Ser 082 and SB 242084. To do so, rats were trained to self-administer meth and tested for seeking-like behavior in cue reactivity sessions consisting of contingently presenting meth-associated cues without meth reinforcement. We also explored motor function to determine the influence of SB 206553 and SDZ Ser 082 on motor activity in the presence and absence of meth. RESULTS: Like mirtazapine, pretreatment with SB 206553 (1.0, 5.0, and 10.0 mg/kg), attenuated meth-seeking. In contrast, the antagonists, SDZ Ser 082 (0.1, 0.3, and 1.0 mg/kg) and SB 242084 (3.0 mg/kg) had no effect on cue reactivity (CR). SB 242084 (3.0 mg/kg) failed to attenuate the effects of 5.0 and 10 mg/kg SB 206553 on CR. Motor function was largely unaltered by the 5-HT(2C) ligands; however, SB 206553, at the highest dose tested (10.0 mg/kg), attenuated meth-induced rearing behavior. CONCLUSIONS: The lack of effect by 5-HT(2C) antagonists suggests that meth-seeking and meth-evoked motor activity are independent of endogenous 5-HT acting at 5-HT(2C) receptors. While SB 206553 dramatically impacted meth-evoked behaviors it is unclear whether the observed effects were 5-HT(2C) receptor mediated. Thus, SB 206553 deserves further attention in the study of psychostimulant abuse disorders.
format Online
Article
Text
id pubmed-3441362
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34413622012-09-14 SB 206553, a putative 5-HT(2C) inverse agonist, attenuates methamphetamine-seeking in rats Graves, Steven M Napier, T Celeste BMC Neurosci Research Article BACKGROUND: Methamphetamine (meth) dependence presents a substantial socioeconomic burden. Despite the need, there is no FDA-approved pharmacotherapy for psychostimulant dependence. We consider 5-HT(2C) receptors as viable therapeutic targets. We recently revealed that the atypical antidepressant, mirtazapine, attenuates meth-seeking in a rodent model of human substance abuse. Mirtazapine historically has been considered to be an antagonist at 5-HT(2C) receptors, but more recently shown to exhibit inverse agonism at constitutively active 5-HT(2C) receptors. To help distinguish the roles for antagonism vs. inverse agonism, here we explored the ability of a more selective 5-HT(2C) inverse agonist, SB 206553 to attenuate meth-seeking behavior, and compared its effects to those obtained with 5-HT(2C) antagonists, SDZ Ser 082 and SB 242084. To do so, rats were trained to self-administer meth and tested for seeking-like behavior in cue reactivity sessions consisting of contingently presenting meth-associated cues without meth reinforcement. We also explored motor function to determine the influence of SB 206553 and SDZ Ser 082 on motor activity in the presence and absence of meth. RESULTS: Like mirtazapine, pretreatment with SB 206553 (1.0, 5.0, and 10.0 mg/kg), attenuated meth-seeking. In contrast, the antagonists, SDZ Ser 082 (0.1, 0.3, and 1.0 mg/kg) and SB 242084 (3.0 mg/kg) had no effect on cue reactivity (CR). SB 242084 (3.0 mg/kg) failed to attenuate the effects of 5.0 and 10 mg/kg SB 206553 on CR. Motor function was largely unaltered by the 5-HT(2C) ligands; however, SB 206553, at the highest dose tested (10.0 mg/kg), attenuated meth-induced rearing behavior. CONCLUSIONS: The lack of effect by 5-HT(2C) antagonists suggests that meth-seeking and meth-evoked motor activity are independent of endogenous 5-HT acting at 5-HT(2C) receptors. While SB 206553 dramatically impacted meth-evoked behaviors it is unclear whether the observed effects were 5-HT(2C) receptor mediated. Thus, SB 206553 deserves further attention in the study of psychostimulant abuse disorders. BioMed Central 2012-06-14 /pmc/articles/PMC3441362/ /pubmed/22697313 http://dx.doi.org/10.1186/1471-2202-13-65 Text en Copyright ©2012 Graves and Napier; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Graves, Steven M
Napier, T Celeste
SB 206553, a putative 5-HT(2C) inverse agonist, attenuates methamphetamine-seeking in rats
title SB 206553, a putative 5-HT(2C) inverse agonist, attenuates methamphetamine-seeking in rats
title_full SB 206553, a putative 5-HT(2C) inverse agonist, attenuates methamphetamine-seeking in rats
title_fullStr SB 206553, a putative 5-HT(2C) inverse agonist, attenuates methamphetamine-seeking in rats
title_full_unstemmed SB 206553, a putative 5-HT(2C) inverse agonist, attenuates methamphetamine-seeking in rats
title_short SB 206553, a putative 5-HT(2C) inverse agonist, attenuates methamphetamine-seeking in rats
title_sort sb 206553, a putative 5-ht(2c) inverse agonist, attenuates methamphetamine-seeking in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441362/
https://www.ncbi.nlm.nih.gov/pubmed/22697313
http://dx.doi.org/10.1186/1471-2202-13-65
work_keys_str_mv AT gravesstevenm sb206553aputative5ht2cinverseagonistattenuatesmethamphetamineseekinginrats
AT napiertceleste sb206553aputative5ht2cinverseagonistattenuatesmethamphetamineseekinginrats